Okuno K, Shigeoka H, Lee Y S, Son E, Kayama H, Nakai T, Koh K, Yasutomi M
First Department of Surgery, Kinki University School of Medicine, Osaka-sayama.
Hepatogastroenterology. 1996 May-Jun;43(9):688-91.
BACKGROUND/AIMS: Based on our favorable results of interleukin-2-based immuno-chemotherapy in the treatment of unresectable liver metastases from colorectal cancer, we utilized this therapy for the prevention of liver recurrence after liver resection.
Eighteen patients with colon cancer metastatic to the liver underwent successful hepatic resection and adjuvant immunochemotherapy that included hepatic arterial infusion of interleukin-2 and mitomycin C, 5-fluorouracil. The regimen consisted of weekly interleukin-2 (1.4-2x 10(6) units), 5-fluorouracil (250 mg) by 2-hour infusion and bolus mitomycin C (4 mg) for 6 months.
Fourteen of 18 patients are alive and disease-free with a median postoperative follow-up of 28.5 months. Recurrent cancer has developed in 4 of the 18 patients (22%). The site of first recurrence was the lung in three patients (17%) and the pelvis in one (6%); no patients recurred in the liver.
We recommend this adjuvant immuno-chemotherapy for the prevention of liver recurrence after curative resection of colorectal liver metastases.
背景/目的：基于我们在使用白细胞介素-2进行免疫化疗治疗不可切除的结直肠癌肝转移方面取得的良好效果，我们将这种疗法用于预防肝切除术后的肝复发。
18例结肠癌肝转移患者成功接受了肝切除及辅助免疫化疗，包括肝动脉灌注白细胞介素-2、丝裂霉素C和5-氟尿嘧啶。治疗方案为每周使用白细胞介素-2（1.4 - 2×10⁶单位）、持续2小时输注5-氟尿嘧啶（250毫克）以及静脉推注丝裂霉素C（4毫克），共6个月。
18例患者中有14例存活且无疾病复发，术后中位随访时间为28.5个月。18例患者中有4例（22%）出现了复发性癌症。首次复发部位在肺部的有3例（17%），在盆腔的有1例（6%）；无患者在肝脏复发。
我们推荐这种辅助免疫化疗用于预防结直肠癌肝转移根治性切除术后的肝复发。
